Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related death in many countries. Approximately half of the patients with non-small cell lung cancer have advanced disease and systemic chemotherapy, especially platinum-based doublets, is currently the standard treatment. Several trials have recently indica...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2011-01-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.4137/CMO.S6252 |
| _version_ | 1830462551260921856 |
|---|---|
| author | Hidetoshi Hayashi Takayasu Kurata Kazuhiko Nakagawa |
| author_facet | Hidetoshi Hayashi Takayasu Kurata Kazuhiko Nakagawa |
| author_sort | Hidetoshi Hayashi |
| collection | DOAJ |
| description | Lung cancer is the leading cause of cancer-related death in many countries. Approximately half of the patients with non-small cell lung cancer have advanced disease and systemic chemotherapy, especially platinum-based doublets, is currently the standard treatment. Several trials have recently indicated the importance of histological subtype for treatment with molecular target chemotherapy and pemetrexed. Over the last decade, gemcitabine, a pyrimidine nucleoside antimetabolite, has been one of the most effective agents for patients with advanced non-small cell lung cancer. It is unknown whether histological type is a predictor of the outcome of treatment with this agent. This is a review of the past trials and reviews of first-line treatment for advanced NSCLC, focusing on efficacy and safety of treatment with gemcitabine according to histological subtype. |
| first_indexed | 2024-12-21T11:47:36Z |
| format | Article |
| id | doaj.art-6205eea2bc89454c8c881f2ce72ff464 |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-12-21T11:47:36Z |
| publishDate | 2011-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-6205eea2bc89454c8c881f2ce72ff4642022-12-21T19:05:08ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492011-01-01510.4137/CMO.S6252Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung CancerHidetoshi Hayashi0Takayasu Kurata1Kazuhiko Nakagawa2Department of Medical Oncology, Kinki University School of Medicine, Osaka-Sayama, Japan.Department of Medical Oncology, Kinki University School of Medicine, Osaka-Sayama, Japan.Department of Medical Oncology, Kinki University School of Medicine, Osaka-Sayama, Japan.Lung cancer is the leading cause of cancer-related death in many countries. Approximately half of the patients with non-small cell lung cancer have advanced disease and systemic chemotherapy, especially platinum-based doublets, is currently the standard treatment. Several trials have recently indicated the importance of histological subtype for treatment with molecular target chemotherapy and pemetrexed. Over the last decade, gemcitabine, a pyrimidine nucleoside antimetabolite, has been one of the most effective agents for patients with advanced non-small cell lung cancer. It is unknown whether histological type is a predictor of the outcome of treatment with this agent. This is a review of the past trials and reviews of first-line treatment for advanced NSCLC, focusing on efficacy and safety of treatment with gemcitabine according to histological subtype.https://doi.org/10.4137/CMO.S6252 |
| spellingShingle | Hidetoshi Hayashi Takayasu Kurata Kazuhiko Nakagawa Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer Clinical Medicine Insights: Oncology |
| title | Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer |
| title_full | Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer |
| title_fullStr | Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer |
| title_full_unstemmed | Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer |
| title_short | Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer |
| title_sort | gemcitabine efficacy in the treatment of advanced stage nonsquamous non small cell lung cancer |
| url | https://doi.org/10.4137/CMO.S6252 |
| work_keys_str_mv | AT hidetoshihayashi gemcitabineefficacyinthetreatmentofadvancedstagenonsquamousnonsmallcelllungcancer AT takayasukurata gemcitabineefficacyinthetreatmentofadvancedstagenonsquamousnonsmallcelllungcancer AT kazuhikonakagawa gemcitabineefficacyinthetreatmentofadvancedstagenonsquamousnonsmallcelllungcancer |